The GRAIL Company in Menlo Park, California has introduced what it calls a first-of-a-kind multi-cancer early detection test called Galleri. Through advancements in genomics research and DNA sequencing, Galleri has the ability to detect more than 50 ...

The Lancet Oncology recently published the results of a phase II clinical trial showing Gemcitabine used in line with the antibody Ramucirumab yielded better clinical outcomes for malignant pleural mesothelioma than Gemcitabine used alone. The study ...

The first-ever study using breath analysis has been shown to differentiate between responders and non-responders of the immunotherapy combination of nivolumab and ipilimumab in mesothelioma patients. Thus, predicting the effectiveness in certain ...